Search our team at AdventHealth Research Institute
-
NCT05761171
AALL2121: A Phase 2 Study of SNDX-5613 in Combination with Chemotherapy for Patients with Relapsed or Refractory KMT2A-Rearranged Infant Leukemia
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe overall goal of this study is to determine the safety and best dose of the drug SNDX-5613 for young children when given in combination with chemotherapy, and to see if this treatment will improve...
-
NCT06203600
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ? 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
This study is currently enrolling.Associated Conditions: Esophageal CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThis study is being done to answer the following questions: Can adding a drug to the usual treatment for advanced stomach and esophageal cancers make it less likely that these cancers will grow or...
-
rhPSMA-7.3(18F)-PET scan to detect prostate cancer in patients with early PSA recurrence.
This study is currently enrolling.Associated Conditions: Prostate CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe research is being done at the Radiology Nuclear Medicine Department of AdventHealth Orlando and Celebration. Patients are instructed to drink water prior to administration of flotufolastat F-18 to...
-
NCT05858164
An open-label, phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics, and tumor response profile of the diacylglycerol kinase alpha inhibitor (DGKai) BAY 2862789 in participants with advanced solid tumors
This study is currently enrolling.Associated Conditions: Metastatic Solid TumorsResearch Area: Cancer ResearchResearch Location: Celebration, FloridaThis study is being done to learn more about a new drug called BAY 2862789, an inhibitor of diacylglycerol kinase alpha (DGKα). BAY 2862789 is an immunotherapy drug that has been developed to activate...
-
NCT05918913
SNDX-5613-0707: Expanded Access Program for SNDX-5613 in Patients with Relapsed/Refractory Acute Leukemias with Genetic Alterations Associated with HOXA Overexpression
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe therapy that will be receive involves being given the drug SNDX-5613 to treat Relapsed/Refractory acute leukemias, including those harboring an KMT2Ar Gene Rearrangement, Nucleophosmin 1 (NPM1m)...
-
NCT06256484
A Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of ATA3219, Allogeneic Anti-CD19 Chimeric Antigen Receptor T-cell Therapy, in Subjects with Relapsed/Refractory B-cell non-Hodgkin Lymphoma
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Orlando, FloridaTo characterize the safety and tolerability of ATA3219 monotherapy in subjects with R/R B-cell NHL. To determine the recommended phase 2 dose (RP2D) of ATA3219 as monotherapy in subjects with R/R B...
-
NCT06226571
A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Orlando, Florida -
NCT06384261
A multicenter, open label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy.
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to see if the investigational study drug, called cusatuzumab, is safe and effective when given together with other standard of care drugs used to treat Acute Myeloid...
-
NCT05987241
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer A032103
This study is currently enrolling.Associated Conditions: Bladder CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThis study is being done to answer the following question: After having your bladder surgically removed after being diagnosed with bladder cancer, can we better identify which patients need an...
-
NCT06307795
A Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
This study is currently enrolling.Associated Conditions: Metastatic Solid TumorsResearch Area: Cancer ResearchResearch Location: Celebration, FloridaThis is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in...
-
NCT06312176
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Altamonte, FloridaThis trial is testing MK-2870 given alone and MK-2870 given with pembrolizumab (MK-2870 plus pembro) in people with advanced breast cancer that cannot be surgically removed.
This trial will compare... -
NCT06500273
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease after Response to First Line Therapy for Large B-Cell Lymphoma (ALPHA3)
This study is currently enrolling.Associated Conditions: LymphomaResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe study is being conducted in patients diagnosed with large B-cell lymphoma who have completed initial therapy. The study aims to see if CAR T cells made from healthy donors are an effective...